---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-039316"
form_type: "8-K"
ticker: "ACLX"
cik: "0001786205"
company_name: "Arcellx, Inc."
filed_at: "2025-02-27T23:59:59+00:00"
generated_at: "2026-05-26T02:23:16.588590+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Arcellx FY2024 net loss $107.3M; anito-cel Phase 2 shows 97% ORR, 62% CR/sCR

## Summary
- Cash, equivalents, and marketable securities $625.7M; runway into 2027.
- Collaboration revenue $107.9M in FY2024 vs $110.3M in FY2023.
- Net loss $107.3M for FY2024 vs $70.7M prior year; R&D spend $157.1M.
- Anito-cel pivotal iMMagine-1 data: 97% ORR, 62% CR/sCR (n=86), no delayed neurotoxicities.
- Commercial launch of anito-cel in RRMM planned for 2026; iMMagine-1 update mid-2025.

## SEC filing metadata
- accession: 0001193125-25-039316
- form_type: 8-K
- ticker: ACLX
- cik: 0001786205
- company_name: Arcellx, Inc.
- filed_at: 2025-02-27T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1786205/000119312525039316/0001193125-25-039316-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1786205/000119312525039316/d904514d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-039316
- JSON: https://secwatch.observer/filing/0001193125-25-039316.json
- Plain text: https://secwatch.observer/filing/0001193125-25-039316.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.